The BioCentury Show
by BioCentury
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 23 chart positions in 23 markets.
By chart position
- 🇺🇸US · Life Sciences#33100K to 300K
- 🇬🇧GB · Life Sciences#34100K to 300K
- 🇦🇺AU · Life Sciences#8230K to 100K
- 🇩🇪DE · Life Sciences#1685K to 30K
- 🇨🇦CA · Life Sciences#1795K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
220K to 700K🎙 ~2x weekly·59 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
440K to 1.4M🇺🇸21%🇬🇧21%🇰🇷21%+20 more - Active Followers
Loyal subscribers who consistently listen
132K to 420K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
Sep 4, 2026
31m 44s
Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient
Aug 21, 2026
29m 57s
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Aug 7, 2026
32m 38s
Ep. 115 - Initiate's Owens on what it takes to be AI-native
Jul 23, 2026
40m 29s
Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model
Jul 10, 2026
41m 59s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 9/4/26 |  Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets | On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics. View full story: https://www.biocentury.com/article/660697 #Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials 0:00 - Introduction 1:14 - Regeneron Genetics Center 10:29 - Acting on Genetic Signals 16:57 ... | 31m 44s | ||||||
| 8/21/26 |  Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient | The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients. In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show, C-Path CEO and CSO Klaus Romero ... | 29m 57s | ||||||
| 8/7/26 |  Ep. 116 - Ovid's Jeremy Levin on biotech in the balance | Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biot... | 32m 38s | ||||||
| 7/23/26 |  Ep. 115 - Initiate's Owens on what it takes to be AI-native | As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model. Owens also discusses gaps in evidence generation for diagnostics, and closes ... | 40m 29s | ||||||
| 7/10/26 |  Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model | Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year. In conversation with Lindsay Martin on The BioCentury Show, Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its ... | 41m 59s | ||||||
| 6/25/26 |  Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking | Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and chief strategy officer, Hengrui is engaging in a range of dealmaking and using its partnerships as stepping stones toward its goal of becoming one of the top biopharma companies in the world. In conversation with Executive Editor Jeff Cranmer on The BioCent... | 35m 06s | ||||||
| 6/18/26 |  Ep. 112 - Chris Arendt on rebuilding Takeda for AI | Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development. View full story: https://www.biocentury.com/article/659807 #Artif... | 40m 29s | ||||||
| 6/12/26 |  Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner | ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch. On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the firs... | 36m 55s | ||||||
| 5/28/26 |  Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China | Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have benefited from the company’s medicines. He has led PDUFA reauthorization negotiations for industry, chaired BIO, and advocated for the interests of mid-sized biotechs. As Pops prepares to retire as CEO (he will remain chairman), he spoke with B... | 37m 37s | ||||||
| 5/15/26 |  Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development | Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.” In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact. As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing r... | 36m 08s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/1/26 |  Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy | A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood. Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s appro... | 33m 21s | ||||||
| 4/17/26 |  Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing | The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally. “We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in... | 37m 40s | ||||||
| 4/3/26 |  Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform | The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving. Mahony, one of the major influential figures in U.K. biotech, is a senior partner in growth investments at Novo Holdings, and was until December chair of the U.K.’s BioIndustry Association (BIA). In conversation with BioCentury Editor in Chief Simo... | 33m 50s | ||||||
| 3/20/26 |  Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers | As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration. View full story: https://www.biocentury.com/article/658829 ... | 39m 32s | ||||||
| 3/6/26 |  Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity | There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower relative to the broader healthcare environment, SoftBank’s Jacqueline Fok said on The BioCentury Show. In conversation with BioCentury's Stephen Hansen, Fok, who is investment director, Life Sciences & Health Tech at SoftBank Investment Advisers, also detailed SoftBank’s inv... | 35m 14s | ||||||
| 2/18/26 |  Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development | Caution: This episode of The BioCentury Show contains strong language. In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slowing drug development and pushing companies to launch early-stage trials outside the U.S. In conversation with BioCentury Washington Editor Steve Usdin, Kolchinsky also discusses U.S. policy headwinds, including most-favored-nation (MFN) pricing proposals and the Inflation R... | 40m 58s | ||||||
| 2/6/26 |  Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs | With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypotheses into usable medicines, says veteran CNS drug developer Steven Paul. Few drug developers have had a closer view of the field’s false starts — and occasional breakthroughs — than Paul, who has moved from NIH to pharma R&D leadership and now to company building at Ka... | 40m 43s | ||||||
| 1/23/26 |  Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms | Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move ideas across the boundaries of biology, manufacturing, regulation and commercialization. That theme threaded through his conversation on The BioCentury Show with Executive Editor Selina Koch, surfacing most clearly in his diagnosis of what Japan’s biotech ecosystem lacks — and i... | 29m 23s | ||||||
| 1/9/26 |  Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next | Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to conduct the technical diligence required for investments once considered too risky for their models. In conversation with The BioCentury Show's Stephen Hansen, Bain Capital’s Adam Koppel discussed the evolution of private equity's interest in biotech, Bain’s prioritization scheme... | 36m 45s | ||||||
| 12/19/25 |  Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma | In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary science, the likes of which we’ve never seen — and it’s getting better,” said Papadopoulos on The BioCentury Show. Papadopoulos is one of the long-term leading voices of biopharma, recognized for his influence in shaping the industry. Former chair of Biogen and current chair of... | 37m 59s | ||||||
| 12/5/25 |  Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw | When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by technological ambition, yet still grappling with many of the structural challenges that defined its beginnings, now compounded by the difficulty of positioning therapies within an ever more complex treatment landscape. Gleevec proved the power of targeting a genomic driver, but the ... | 37m 38s | ||||||
| 11/27/25 |  Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future | This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Back to School essay, authored by BioCentury Washington Editor Steve Usdin, who has been a leading voice on regulation and policy for over two decade... | 38m 39s | ||||||
| 11/14/25 |  Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science | Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic career. In 2002, he was nominated and confirmed as NIH director, and later he served in senior positions in the biopharma industry. That trajectory “would be almost impossible” today, he told BioCentury Washington Editor Steve Usdin on The BioCentury Show. Anti-immigration polic... | 34m 11s | ||||||
| 10/31/25 |  Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook | It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though her first gig as a biotech CEO, Kornowski’s success was built on her years of experience as head of partnering at Roche. She discussed that pivot and the value of rolling your sleeves up on the latest episode of The BioCentury Show. View full story: https://www.biocentury.com... | 32m 17s | ||||||
| 10/16/25 |  Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem | Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of biopharma’s most closely watched new therapeutic modalities, Kymera is now over nine years into its story, with multiple pharma partnerships and a wholly owned pipeline, including a STAT6 degrader that produced promising data in June. In conversation with BioCentury’s Selina Koch... | 31m 33s | ||||||
Showing 25 of 70
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart history for The BioCentury Show
Peaked at #13 in South Korea, currently #13 in South Korea.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| South Korea | — | #13 | #13 | — |
| United States | — | #33 | #33 | — |
| United Kingdom | — | #34 | #34 | — |
| CH | — | #34 | #34 | — |
| MY | — | #35 | #35 | — |
| SG | — | #38 | #38 | — |
| Sweden | — | #49 | #49 | — |
| IL | — | #58 | #58 | — |
| France | — | #63 | #63 | — |
| AE | — | #64 | #64 | — |
| Japan | — | #72 | #72 | — |
| HK | — | #75 | #75 | — |
| GR | — | #77 | #77 | — |
| South Korea | — | #80 | #80 | — |
| Australia | — | #82 | #82 | — |
| AT | — | #99 | #99 | — |
| BE | — | #107 | #107 | — |
| Netherlands | — | #134 | #134 | — |
| PL | — | #150 | #150 | — |
| Germany | — | #168 | #168 | — |
Chart Positions
24 placements across 23 markets.
Chart Positions
24 placements across 23 markets.